All In Biotech

Drug Trial Radar · NCT06912295

Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of HL-1186 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

76

Planned (sponsor's estimate)

Start

Mar 21, 2025

Primary completion

Aug 30, 2025

Study completion Oct 9, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This single-center, randomized, double-blind, placebo-controlled, two-part study is designed to assess the safety, tolerability and PK of oral HL-1186 Tablet in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • HL-1186Drug

    HL-1186 tablet for oral administration.

  • HL-1186 placeboDrug

    HL-1186 placebo tablet for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of single and multiple doses of HL-1186 in healthy participantsTime frame: Single ascending dose(SAD): day1 to day14; Food effect(FE): day1 to day21; Multiple ascending dose(MAD): day1 to day27

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangnan University Affiliated Hospital

    Wuxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.